LONDON–(BUSINESS WIRE)–Apr 28, 2020–
The global bleeding disorders therapeutics market is expected to grow by USD 4.32 billion as per Technavio. This marks a significant market slowdown compared to the 2019 growth estimates due to the impact of the COVID-19 pandemic in the first half of 2020. However, healthy growth is expected to continue throughout the forecast period, and the market is expected to grow at a CAGR of almost 7%.
This press release features multimedia. View the full release here:
Technavio has announced its latest market research report titled Global Bleeding Disorders Therapeutics Market 2020-2024 (Graphic: Business Wire)
The market is driven by rising initiatives to increase awareness. In addition, the R&D of novel therapies is anticipated to boost the growth of the bleeding disorders therapeutics market.
Private and government organizations across the world are undertaking various initiatives to create awareness about the availability of medicines for bleeding disorders. For instance, the World Federation of Hemophilia marked April 27th as the World Hemophilia Day. In 2019, during this initiative, the organization conducted several educational events and regional workshops to create awareness about bleeding disorders through media coverage and training programs. Many such awareness programs and campaigns are leading to the demand for bleeding disorder therapeutics, thereby driving the growth of the market.
Baxter International Inc. operates its business through segments such as Renal care, Medication Delivery, Pharmaceuticals, Advanced surgery, Acute therapies, and Other. Some of the key offerings of the company include FEIBA, HEMOFIL M, RIXUBIS, and Prothromplex TOTAL.
Bayer AG operates its business through segments such as Pharmaceuticals, Crop science, Consumer health, and Animal health. Some of the key offerings of the company include Jivi, KOVALTRY, and Kogenate FS.
CSL Ltd. operates its business through segments such as CSL Behring and Seqirus. Corifact, RiaSTAP, Stimate, Humate-P, AFSTYLA, IDELVION, and MONONINE are some of its key offerings.
F. Hoffmann-La Roche Ltd. operates its business through segments such as Pharmaceuticals and Diagnostics. HEMLIBRA is one of its key offerings. It is a prophylactic treatment for patients with hemophilia A with or without factor VIII inhibitors.
Grifols SA operates its business through segments such as Bioscience, Hospital, Diagnostic, Bio-supplies, and Others. ALPHANATE, Profilnine SD, and AlphaNine SD are some of its key offerings.
– Global hemophilia market by type (hemophilia A, hemophilia B, and hemophilia C) and geography (North America, Europe, Asia, and ROW).
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
View source version on businesswire.com:
CONTACT: Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email:media@technavio.com
Website:www.technavio.com/
KEYWORD:
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Technavio Research
Copyright Business Wire 2020.
PUB: 04/28/2020 08:00 PM/DISC: 04/28/2020 08:01 PM
COMMENTS
Please let us know if you're having issues with commenting.